Stock NOVN NOVARTIS AG
Add to a list
To use this feature you must be a member
Log inSign up

Financials Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange
Other stock markets
 11:30:41 2024-05-31 am EDT 		5-day change 1st Jan Change
93.17 CHF +2.13% Intraday chart for Novartis AG +1.56% +9.78%
May. 31 NOVARTIS AG : UBS reiterates its Buy rating ZD
May. 31 European Equities Close Higher in Friday Trading; Flash Euro Area Inflation Rises More Than Expected MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 214,715 215,682 196,476 194,400 207,226 210,402 - -
Enterprise Value (EV) 1 230,615 240,182 204,667 203,434 219,237 222,469 221,014 215,148
P/E ratio 30.4 x 26.7 x 8.2 x 28.3 x 14.1 x 20 x 17.3 x 16 x
Yield 3.19% 3.56% 3.83% 3.87% 3.79% 3.51% 3.64% 3.82%
Capitalization / Revenue 4.53 x 4.43 x 3.81 x 3.85 x 4.56 x 4.29 x 4.11 x 4.05 x
EV / Revenue 4.86 x 4.94 x 3.96 x 4.02 x 4.82 x 4.53 x 4.32 x 4.14 x
EV / EBITDA 14.6 x 14.3 x 11.2 x 10.9 x 12.2 x 11.5 x 10.6 x 10.1 x
EV / FCF 17.9 x 20.5 x 15.4 x 17 x 16.6 x 16.1 x 14.4 x 13.3 x
FCF Yield 5.58% 4.87% 6.49% 5.87% 6.01% 6.22% 6.96% 7.54%
Price to Book 3.87 x 3.78 x 2.9 x 3.23 x 4.42 x 4.57 x 4.52 x 4.23 x
Nbr of stocks (in thousands) 2,264,608 2,274,506 2,237,092 2,150,980 2,055,460 2,040,406 - -
Reference price 2 94.81 94.83 87.83 90.38 100.8 103.1 103.1 103.1
Announcement Date 1/29/20 1/26/21 2/2/22 2/1/23 1/31/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 47,445 48,659 51,626 50,545 45,440 49,081 51,178 51,908
EBITDA 1 15,809 16,845 18,246 18,613 17,937 19,298 20,849 21,266
EBIT 1 14,112 15,416 16,588 16,665 16,372 18,187 19,323 19,678
Operating Margin 29.74% 31.68% 32.13% 32.97% 36.03% 37.05% 37.76% 37.91%
Earnings before Tax (EBT) 1 8,940 9,878 26,137 8,371 9,123 13,255 14,695 15,277
Net income 1 7,147 8,072 24,021 6,955 14,854 10,482 11,741 12,641
Net margin 15.06% 16.59% 46.53% 13.76% 32.69% 21.36% 22.94% 24.35%
EPS 2 3.120 3.550 10.71 3.190 7.150 5.151 5.977 6.457
Free Cash Flow 1 12,875 11,691 13,282 11,945 13,179 13,834 15,386 16,219
FCF margin 27.14% 24.03% 25.73% 23.63% 29% 28.19% 30.06% 31.25%
FCF Conversion (EBITDA) 81.44% 69.4% 72.79% 64.18% 73.47% 71.68% 73.79% 76.27%
FCF Conversion (Net income) 180.15% 144.83% 55.29% 171.75% 88.72% 131.98% 131.04% 128.31%
Dividend per Share 2 3.025 3.375 3.360 3.500 3.823 3.622 3.756 3.939
Announcement Date 1/29/20 1/26/21 2/2/22 2/1/23 1/31/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 13,229 12,531 12,781 12,543 12,690 12,953 13,622 11,782 11,423 11,829 12,257 12,470 12,667 12,260 12,510
EBITDA 4,274 4,407 4,989 4,783 4,473 - 4,668 - 4,224 - - - - - -
EBIT 1 3,819 4,083 4,270 4,282 4,030 4,413 4,668 4,405 3,821 4,537 4,623 4,750 4,543 4,980 4,920
Operating Margin 28.87% 32.58% 33.41% 34.14% 31.76% 34.07% 34.27% 37.39% 33.45% 38.35% 37.72% 38.09% 35.87% 40.62% 39.33%
Earnings before Tax (EBT) 1 16,951 2,669 2,042 1,919 1,741 2,740 2,769 1,552 2,377 3,129 3,856 3,879 3,664 - -
Net income 1 16,308 2,222 1,695 1,575 1,466 2,293 2,316 1,513 8,480 2,688 2,777 2,814 2,515 - -
Net margin 123.27% 17.73% 13.26% 12.56% 11.55% 17.7% 17% 12.84% 74.24% 22.72% 22.65% 22.56% 19.86% - -
EPS 2 7.290 1.000 0.7700 0.7300 0.6900 1.090 1.110 0.7300 4.140 1.310 1.358 1.386 1.252 - -
Dividend per Share 2 3.360 - - - 3.500 - - - 3.823 - 0.9587 0.9587 0.9587 1.024 1.024
Announcement Date 2/2/22 4/26/22 7/19/22 10/25/22 2/1/23 4/25/23 7/18/23 10/24/23 1/31/24 4/23/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 15,900 24,500 8,191 9,034 12,011 12,067 10,612 4,745
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.006 x 1.454 x 0.4489 x 0.4854 x 0.6696 x 0.6253 x 0.509 x 0.2231 x
Free Cash Flow 1 12,875 11,691 13,282 11,945 13,179 13,834 15,386 16,219
ROE (net income / shareholders' equity) 17.5% 23.5% 22.7% 21% 25.4% 32.9% 38.5% 37.6%
ROA (Net income/ Total Assets) 8.89% 6.45% 10.9% 10.7% 12.4% 10.7% 12.8% 14.2%
Assets 1 80,393 125,215 221,201 64,915 120,082 97,523 91,739 88,933
Book Value Per Share 2 24.50 25.10 30.30 28.00 22.80 22.60 22.80 24.40
Cash Flow per Share 2 5.880 5.950 6.670 6.480 6.910 7.790 8.430 8.720
Capex 1 2,257 1,275 1,378 1,198 1,060 1,195 1,271 1,325
Capex / Sales 4.76% 2.62% 2.67% 2.37% 2.33% 2.43% 2.48% 2.55%
Announcement Date 1/29/20 1/26/21 2/2/22 2/1/23 1/31/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Novartis AG

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
103.1 USD
Average target price
108.8 USD
Spread / Average Target
+5.50%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
NOVARTIS AG Stock Novartis AG
+9.78% 206B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 734B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 591B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 350B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 315B
ABBVIE INC. Stock AbbVie Inc.
+4.05% 276B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 238B
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 204B
AMGEN INC. Stock Amgen Inc.
+6.17% 161B
PFIZER, INC. Stock Pfizer, Inc.
-0.45% 160B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. NOVN Stock
  4. Financials Novartis AG